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Xenotropic murine leukemia virus-related virus (XMRV) was ﬁrst reported in 2006 in a study of human prostate cancer patients
with genetic variants of the antiviral enzyme, RNase L. Subsequent investigations in North America, Europe, Asia, and Africa have
either observed or failed to detect XMRV in patients (prostate cancer, chronic fatigue syndrome-myalgic encephalomyelitis (CFS-
ME),andimmunosuppressedwithrespiratorytractinfections)ornormal,healthy,controlindividuals.Theprincipalconfounding
factors are the near ubiquitous presence of mouse-derived reagents, antibodies and cells, and often XMRV itself, in laboratories.
XMRV infects and replicates well in many human cell lines, but especially in certain prostate cancer cell lines. XMRV also traﬃcs
to prostate in a nonhuman primate model of infection. Here, we will review the discovery of XMRV and then focus on prostate
cancer-related research involving this intriguing virus.
1.Introduction
The retrovirus, xenotropic murine leukemia virus-related
virus (XMRV), has generated both interest and debate
within the scientiﬁc community and also among physicians,
patients, and those concerned with maintaining the safety
of blood and tissue banks around the world (reviewed in
[1–3]). Its discovery was based on the hypothesis that viral
infectionsmightcontributetohereditaryprostatecancer[4].
Currently, seven types of viruses (HPV, EBV, HHV-8, HTLV-
1, HBV, HCV, and MCV) are established etiologic agents
of diﬀerent types of human cancers [5, 6]. While there is
also evidence for the presence of viral infections in prostate
cancer, including BKV [7], HPV [8, 9], HCMV [10], and
EBV [11], thus far there is no compelling evidence that links
viral infections to this disease. However, family history is
a risk factor for prostate cancer, and in 2002, a combined
positional cloning and candidate gene approach mapped
a hereditary prostate cancer susceptibility locus, HPC1 at
1q24-25 [12, 13], to the gene encoding the antiviral protein,
RNase L [14]. While several studies have described a link
between RNASEL and hereditary prostate cancer [14–18],
other studies have been unable to conﬁrm the association
[19–22]. RNase L is one of the principal antiviral proteins
in innate immunity [23]. Type I interferons produced during
viral infections induce the pathogen recognition receptors,
OAS1 to 3, which produce 2 ,5 -oligo(rA) from ATP in
response to viral double-stranded RNA. RNase L is present
in most mammalian cell types and is activated upon binding
to 2 ,5 -oligo(rA), thus blocking viral infections by means of
RNA degradation [24]. Many diﬀerent types of viruses are
susceptible, in particular viruses with single-stranded RNA
genomes, including the retrovirus HIV-1 [25]. The mapping
of HPC1 to RNASEL and the invention of a global viral DNA
microarray (aka virochip) provided the impetus and means
for renewing the search for viruses in prostate cancer [26].
The realization that an HPC gene encoded an antiviral
protein further suggested the possible involvement of viral
infections in prostate cancer. To test this hypothesis, men
with localized prostate cancer were genotyped for the R462Q
(1385nt G→A) variant of RNASEL. A prior study showed
that when homozygous this variant doubled the risk of
prostate cancer and was implicated in up to 13% of cases
[27]. The RNase L Q variant also has about 3-fold reduced2 Advances in Virology
enzymatic activity compared with the wildtype R variant
[27,28].Followingradicalprostatectomy,RNAisolatedfrom
prostate tumors was converted to labeled cDNA and used
to screen for evidence of viral sequences by hybridization
to virochips composed of the most conserved sequences
of all known human, animal, plant, and bacterial viruses
[4, 26, 29]. Because the array contained highly conserved
sequences within viral nucleic acids, it can detect viruses
not explicitly represented. These studies identiﬁed the pres-
ence of a γretrovirus in 8 (40%) of 20 RNase L R462Q
homozygous prostate cancer tissues, and in just 1 (1.5%) of
66 tissues that harbored at least one copy of the wildtype
allele (Figure 1). Three XMRV genomes were completely
sequenced and were found to share >98% nucleotide and
>99% protein sequence identity. Partial sequences were
obtained for another six XMRV strains. XMRV is more
closely related to the xenotropic and polytropic than to
the ecotropic murine retroviruses. XMRV is a canonical
γretrovirus, with gag, pro-pol, and env genes, and is not
closely related to any endogenous human retroviral (HERV)
elements (Figure 2). In addition, XMRV sequences are not
present in any human genomic sequences that have been
reported to date. A complete provirus clone for XMRV strain
VP62 produced infectious virus in LNCaP or DU145 cells
[30, 31]. XMRV is able to vigorously infect these and some
other cell lines, in particular some prostate cancer cell lines
[30, 32–34], allowing for basic virology studies in cell culture
system to be conducted. A timeline of XMRV research shows
that there was a lag prior to 2010 when a large increase in
research papers on the subject appeared in peer-reviewed
scientiﬁc journals (Figure 3).
2. Evidence for and against XMRV in
ProstateCancer
The possibility of laboratory contamination was carefully
considered in the XMRV discovery paper in which several
lines of evidence supported genuine human infections [4].
First, XMRV was detected using (DNase-treated) RNA
directly isolated from fresh frozen, primary human prostate
tumor tissues that were not placed in cell culture nor were
these human samples exposed to any cultured cell products
or cell culture reagents. Second, the extent of sequence
variation between the diﬀerent gag and pol sequences from
diﬀerent prostate cancer patients was greater than Taq
polymerase error rates which range from 10−6 to 10−4 (see
[66] and references therein). These ﬁnding suggested natural
sequence diversity consistent with independent acquisition
of XMRV infections by humans. Third, ﬂuorescence in situ
hybridization (FISH) identiﬁed XMRV nucleic acid in a
small number of stromal cells in tumor-bearing prostate
tissue. Fourth, a similar small number of Gag-positive
stromal cells were detected in prostate tumor tissues using
monoclonal antibody against spleen focus-forming virus
Gag with an enhanced alkaline phosphatase red detection
method. Fifth, no mouse GAPDH DNA sequences were
detected in any of the radical prostatectomy samples pro-
viding evidence against contamination from any mouse-
derivedsources.Finally,XMRVwaspredominantlyrestricted
to RNase L QQ prostate cancer cases. Therefore, both PCR
based and non-PCR evidence supported genuine infection
of humans.
Recently, however, the human origin of XMRV has been
questioned based in part on the near sequence identity of
XMRV strain VP62, isolated using human prostate cancer
tissue, with XMRV present in a human prostate cancer cell
line, 22Rv1 [33]. The 22Rv1 cells were derived in the 1990s
at Case Western Reserve University from a human prostate
cancer xenograft by serial passage in mice after castration-
induced regression and relapse, raising the possibility that
the virus in those cells originated from the mice rather than
the patient [67]. A recent study shows that variation between
XMRV sequences in the 22Rv1 cell lines exceeded that of
XMRV sequences isolated from human specimens, leading
theauthorstoproposethatXMRVmightnotbeanauthentic
human pathogen [59]. In addition, a recent study concludes
that the XMRV in 22Rv1 cells originated from two MLV
genomes present in the mice used to passage the xenografts
([45], 18th Conference on Retroviruses and Opportunistic
Infections).
Additional evidence in favor of genuine infections,
including some of the same prostate cancer patients as in the
discovery study [4], was provided by XMRV integration site
mapping experiments [30, 35]. DNA isolated from human
prostate tissues in a PCR-amplicon-free clean room were
sent to UCLA and used to precisely map and sequence
XMRV integrations sites in nine separate prostate cancer
patients [30, 35]. In these prostate cancer tissues, there was a
greater tendency for XMRV to integrate near cancer-related
genes, microRNA genes, common fragile sites, and cancer
breakpoints in comparison to XMRV integration sites in
DU145 prostate cancer cells infected in the lab [35]. Those
results suggested an in vivo selection process for XMRV
integrations in certain genes. The viral integration sites in
human prostate DNA started precisely after the end of the
right-side LTR repeat (5 -···CTTTCA-3 ) demonstrating
correct integration had occurred and ruling out artifactual
fusion. These experiments also eﬀectively ruled out direct
mouse DNA contamination as a source of the XMRV
sequences because LTR sequences were fused to human,
not mouse, DNA. However, two of the integration sites are
identical to XMRV integration sites obtained with XMRV-
infected DU145 cells used in the same studies [35, 68, 69].
Therefore, it remains to be conﬁrmed whether these two
sites, and the other 12 XMRV integration sites, originated
from the patients or from cells infected in the laboratory.
Three independent studies supported XMRV infections
of prostate cancer patients at prevalence rates in the range
of about 10 to 28%. A study from the University of Utah
and Columbia University produced evidence for XMRV
infection of prostatic malignant epithelial cells in vivo [31].
Immunohistochemistry (IHC) performed on 233 prostate
cancer specimens and 101 controls with benign prostatic
hyperplasia showed protein staining for XMRV in 23% of
cancer cases and 4% of controls. IHC was performed using
a polyclonal antibody raised in rabbit against whole virus
XMRV (produced in 293T cells—a human kidney epithelial
cell line). The presence of antibodies against host-derivedAdvances in Virology 3
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Figure 1:XMRVdiscoveryinprostatecancerstudy[4].Humanprostatecancertissueswerecollected intheoperatingroomattheCleveland
Clinic and used to isolate RNA at either the Cleveland Clinic or at UCSF. At UCSF, RNA was used to synthesize labeled cDNA, virochips
were probed, RT-PCR was performed for gag sequences, and XMRV cDNAs were sequenced. The RNase L genotypes were determined at the
Cleveland Clinic (also the site of the IHC and FISH experiments, not shown). A hybridization pattern typical of a γretrovirus was obtained
almost exclusively from patients with the RNase L QQ genotype (red bands and VP codes for QQ patients). RNase L RQ and RR genotypes
are shown in black VP codes.
proteins among the anti-XMRV antibodies is a limitation of
this approach and raises questions about whether the signals
detected originated from XMRV infections. Quantitative
PCR data from the same study detected XMRV DNA in 6.2%
of prostate cancer and 2.0% of control specimens, much
lower percentages than through IHC. XMRV associated with
higher Gleason Index of prostate cancer but there was no
correlationwiththeR462QRNaseLvariant[31].Thisreport
suggestedthatXMRVisapossibleetiologicagentforprostate
cancer, and not just a passenger virus.
An investigation at Emory University conﬁrmed the
presence of XMRV in men with prostate cancer by utilizing
three methods, a novel serum-based assay for neutralizing
antibodies against XMRV, nested PCR for env sequences,
and FISH [53]. The serologic assay detected neutralizing
antibodies in 11 of 40 prostate cancer cases (27.5%). Among
20 RNASEL QQ patients, 8 (40%) had neutralizing antibody
against XMRV, in agreement with the original report of an
association of XMRV infection with the QQ genotype [4].
FISH showed XMRV infection in 5–8% of stromal cells of
positive cases, and none in epithelial cells [53]. All three
methods were in agreement for 5 XMRV positive cases and
2 XMRV negative cases.
Most recently, a study at Baylor University detected
XMRV in 32 of 144 (22%) men from the southern US
with prostate cancer using a nested PCR assay for the env
gene [54]. Patients were more likely to score positive for
the presence of XMRV in both tumor and normal tissue
than in either type of tissue alone. However, there was no
correlation between the presence of XMRV and either the
RNase L genotype or clinical parameters of disease. The
presence of XMRV in normal tissues suggested that infection
might precede prostate cancer.
In support of the presence of XMRV in some prostate
cancer patients, a follow-up study at the Cleveland Clinic
detected XMRV RNA by nested and quantitative RT-PCR of
env RNA in expressed prostate secretions of 4 of 32 unse-
lected prostate cancer cases [70]. These ﬁndings suggested
that XMRV might be present in human semen. However,
anotherstudyusingnestedRT-PCRofXMRVgag RNAfailed
todetectXMRVinseminalplasmafromHIV-1-infectedmen
in the Netherlands, although some of these subjects were
using antiretroviral drugs [71].
Several research eﬀorts have either failed to detect XMRV
at all, or demonstrated very low prevalence of infection.
In the ﬁrst of several European studies, an investigation in4 Advances in Virology
Envelope
proteins
SU (gp70)
PR
RT, IN
TM (p15E)
MA (p15)
CA (p30)
NC (p10)
gag pol env
p12
Core
proteins
Core
proteins Reverse
transcriptase
RNA genome
Envelope
proteins
5 
5 -UTR 3 -UTR
AAAAAA ··· 3 
(a)
100nm
(b)
Figure 2: XMRV structure and morphology. (a) Structure of xenotropic murine leukemia virus-related virus showing viral core proteins
from the gag gene (matrix (MA), capsid (CA), (IN), and nucleocapsid (NC) and p12); from pol (protease (PR), reverse transcriptase (RT),
and integrase (IN)) and the envelope proteins (surface subunit (SU) and transmembrane subunit (TM) from env). Viral particles contain
a lipid bilayer envelope and two RNA genomes. (b) Transmission electron microscope image of XMRV (courtesy of Dr. John Hackett, Jr.,
Abbott Diagnostics, Abbott Park, IL).
Hamburg, Germany found XMRV RNA by nested RT-PCR
inonlyoneof87casesinnonfamilialprostatecancerandone
of 70 samples from a control population of men with benign
prostatic hyperplasia [36]. Both patients contained at least
one copy of the wildtype R462 RNase L allele. A study from
Berlin failed to detect XMRV in 589 prostate cancer tissues
and 146 prostate cancer serum samples utilizing nested PCR
for gag DNA, RT-PCR for gag RNA, and serology assays
for antibodies against XMRV Gag and Env. RNASEL status
was examined in 76 patients in which 12.9% were QQ [42].
Further studies from Europe demonstrated similar negative
results. Using PCR, a study of prostate cancer patients in
Ireland found no evidence of XMRV DNA by PCR in 139
peripheral blood mononuclear cell (PBMC) samples nor in
prostate tissues of seven RNASEL QQ prostate cancer cases
and two RQ cases, although the QQ genotype was associated
with more aggressive disease [72]. A Dutch study of tissue
specimens for 74 sporadic prostate cancer patients showed
low detection (1 in 600 to 7,000 cells) in only three cases
(4%) using RT-PCR for XMRV integrase sequences [73]. An
international collaborative study centered in the UK utilized
nested PCR with gag leader primers on DNA extracted
from formalin-ﬁxed and paraﬃn-embedded (FFPE) prostate
cancer tissues from the UK, Thailand, and Korea [60].
XMRV-like sequences were detected in 14/292 UK prostate
cancers, 5/139 Korean samples, and 2/6 specimens from
Thailand. However, upon sequencing, some ampliﬁed DNA
fragments contained the 24nt deletion upstream of the
gag ATG start codon while other amplicons more closely
resembled polytropic MLV. Because these results suggested
contamination with mouse DNA, a single PCR assay for
intracisternal A-type particle (IAP) LTR sequences and a
TaqMan qPCR assay for mouse mitochondrial cytochrome
oxidase, cox2, sequences were performed. These assays are
highly sensitive due to large numbers of copies per mouse
cell. The presence of the PCR products using XMRV gag
leader primers in the human DNA samples was completely
concordantwithIAPsequences,themoresensitiveofthetwo
assaysformouseDNAcontamination.Therefore,all“XMRV
positive” samples were also contaminated with mouse DNA
contamination.
Within North America, negative results have also been
reported. In Mexico, XMRV RNA was assayed by nested
RT-PCR with only a single positive out of 75 controls
with an RNase L RR genotype, and no positives among 55
prostate cancer patients, none of which were QQ genotype
[9]. An investigation of diﬀerent bacteria and viruses in
prostate cancer found no XMRV DNA in 200 patients
using nested PCR to gag [74]. More recently a report that
included some of the same authors published an absence
of XMRV in over 800 specimens using both RT-PCR and
IHC [55]. A duplex PCR assay was used on DNA from 161
prostatic adenocarcinomas in which XMRV gag sequences
were coampliﬁed with a host gene, but no XMRV wasAdvances in Virology 5
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Figure 3: Timeline of XMRV research. Highlights of XMRV studies are shown, including many of the investigations discussed in this review.
The mapping of HPC1 to RNASEL was reported in 2002 [14] which led to the discovery of XMRV in 2006 using virochip technology [4]. In
2007,theﬁrstinfectiouscloneofwasconstructedbyfusingtwooverlappingcDNAfromprostatecancerpatientVP62[30].Inaddition,XPR1
was identiﬁed as the receptor for XMRV and the ﬁrst integration sites in humans were reported [30]. In 2008, additional integration sites
were mapped using human prostate cancer tissues [35]. A very low prevalence of XMRV was reported in sporadic prostate cancer patients
in Germany [36]. In 2009, XMRV was identiﬁed in the human prostate cancer cell line 22Rv1, which had been repeatedly implanted and
g r o w ni nm i c e[ 33]. In addition, a report of XMRV in prostatic malignant epithelium that correlated with tumor aggressiveness appeared
[31]. The same year, a study using multiple methods of detection, including PCR, a serology assay for Env and isolation of live virus,
showed XMRV in blood of CFS-ME patients, with much lower rates in healthy controls [37]. Studies into XPR1 function and speciﬁcity
were reported between 2008 and 2010 [34, 38–41], including a study showing that whereas most laboratory strains of mice were resistant to
infections, wild mice were susceptible [39]. A study from Germany that used PCR and antibody detection found no evidence of XMRV in
prostate cancer [42]. In 2010, the androgen stimulatory eﬀect on XMRV transcription and replication was reported [32, 43]. Host restriction
factors, such as APOBEC3G and tetherin, were found to be active against XMRV [44–48]. Antiretroviral drugs were screened and some
found to potently inhibit XMRV replication in cell culture [48–50]. The Asian mouse, Mus pahari, was exploited for studies on in vivo
infection [50]. MLV-related sequences were found to associate with CFS-ME [51]. Meanwhile, several other studies, based on PCR and
serology, failed to detect XMRV in CFS-ME (e.g., [52]). Two studies conﬁrmed XMRV infections of prostate cancer patients [53, 54] while
other studies failed to detect XMRV in prostate cancer patients in the US [55, 56]. Several assays for the detection of XMRV, including a
high-throughput automated assay for antibodies against XMRV proteins, were reported [57]. XMRV was reported at a prevalence of almost
10% in immunosuppressed patients with respiratory tract infections in Germany [58]. Papers were published on laboratory contamination
with mouse DNA that confounded the search for XMRV in humans [56, 59–62]. In early 2011, a study on XMRV in a non-human primate
model showed wide-spread, persistent infection, including the prostate [63]. The crystal structure of the XMRV protease was published [64].
Finally, stimulation of XMRV transcription by proinﬂammatory cytokines through an NF-κB element in the LTR appeared [65].
detected. The assay was capable of detecting DNA from a
single XMRV infected cell, 22Rv1, in the presence of a large
excess of human DNA. In addition, 596 prostate cancers and
452 benign prostate tissue specimens were screened by IHC
and all were negative. Recently, prostate tissue DNA from
US patients with intermediate- to advanced-stage prostate
cancer were tested by PCR assays for XMRV and MLV
variants [75]. In three of 162 cases (1.9%), XMRV DNA
was detected and sequenced. These samples were negative
for mouse mitochondrial DNA using a highly sensitive assay,
ruling out contamination from mouse DNA. There was
no association with the RNase L QQ variant, plasma was
negative for viral RNA by RT-PCR and all 162 patients
were negative by a Western blot assay for antibody. The
authors concluded that there was no association of XMRV
or MLV variants with prostate cancer. However, they also
concluded that there was a distinctive XMRV strain in 3
cases, demonstrating a broader diversity in this family of6 Advances in Virology
viruses while supporting the case for human infections.
A recent study of 110 prostate cancer cases and 40 benign or
normal prostate tissues from the Midwestern US concluded
noassociationwithXMRV[56].Althoughtherewere6PCR-
positive cases for MLV sequences (5 prostate cancer and
1 nonprostate cancer) all of these were positive for mouse
mitochondrial DNA suggesting contamination. There were
sporadic IHC-positive prostate tissues using anti-XMRV
antibody [31] but not with an anti-MLV antibody, and none
of the serum samples produced strong neutralization of
XMRV infections.
While the reasons for these disparate results have yet to
be fully resolved, there are several possibilities. For instance,
XMRV may be present at extremely low levels in vivo
and therefore the virus could be missed. Because a single
provirus can be transcribed into large numbers of RNA
transcripts, detection of RNA may be more sensitive than
that of DNA. Diﬀerences in geographical distribution of the
virus, patient selection criteria, and methodology (e.g., PCR
for env versus gag and tissue processing—e.g., fresh-frozen
tissue versus formalin-ﬁxed and paraﬃn-embedded tissues)
are other variables. In some instances positive ﬁndings could
be tainted by laboratory or reagent contamination, as is
the case for mouse nucleic acids in some preparations of
Platinum Taq polymerase (Invitrogen) used in PCR [1, 61].
Three examples of laboratory contamination have recently
been published, two in prostate cancer specimens already
mentioned [56, 60], the other in CFS-ME [62]. Because of
the close relationship of XMRV sequence to sequences in
mousegenomes,bothextraordinarymeasurestoavoidcross-
contamination and ultrasensitive methods for detection of
mouse DNA and RNA are necessary.
3. The Xenotropic and PolytropicRetrovirus
Receptor 1 (XPR1) inHumanProstaticCells
XPR1 is the cell surface receptor and determinant of viral
infectivity for XMRV, X-MLVs, and P-MLVs [30, 34, 38, 39,
76–78]. It is a 696aa protein with eight putative transmem-
brane domains and four putative extracellular loops (ECL1–
4) [76–78]. Despite a common receptor, XMRV has host
rangeandreceptorrequirementsthatdiﬀerfrommouseX/P-
MLVs, suggesting adaptations in humans or in intermediate
hosts. Residues K500 and T582 in XPR1 ECL3 and ECL4,
provideequivalentreceptorsforX/P-MLV,butnotinthecase
ofXMRV[40].Inaddition,mouseX-MLVisabletoinfectall
mammals, but XMRV is unique in being restricted in gerbil
and hamster cells [40]. There are at least six functionally
distinct variants of the XPR1 receptor with varying abilities
to support entry by X-MLVs and P-MLVs [41]. While it is
unknown whether XMRV found in humans was transmitted
directly from infected mice, direct transmission could be
reﬂected in the geographical distribution of virus and/or
receptortypeinmice,aswellasintheworldwidedistribution
of prostate cancer cases. Interestingly, the most permissive
Xpr1 receptor allele, Xpr1sxv, is found in areas of high
prostate cancer incidence such as the United States, while
the most restrictive allele, Xpr1m, is found in low tumor rate
areas such as Japan and Eastern Europe [38].
XPR1 RNA was shown to be present in human prostate
stromal ﬁbroblasts but absent in prostatic epithelial and
smooth muscle cell lines [79], consistent with some previous
ﬁndings that XMRV viral antigens are present in prostatic
stromal ﬁbroblasts of prostate cancer patients [4, 53].
However, prostate cancer cells of epithelial origin express
XPR1 and are susceptible to XMRV infection [34]. XMRV
was able to infect, at low levels, cells that did not express
detectable levels of XPR1 RNA, suggesting an alternative
pathway of infection [79].
4. Enhancement of XMRV Infectivity by Fibrils
of ProstaticAcid Phosphatase Fragments
Prostatic acid phosphatase is the predominant protein in
human semen, and fragments of this protein form positively
charged amyloid ﬁbrils that signiﬁcantly increase HIV-1
infectivity [80]. These ﬁbrils, aka “semen enhancers of virus
infection”(SEVI),capturevirusparticlesandgreatlyincrease
viral attachment and entry via cell surface receptors by
neutralizing negative-charge repulsion between the HIV-1
virion and the cell surface [81]. SEVI has also been shown
to enhance XMRV infections via the XPR1 receptor in
human prostate cancer cell line DU145 [70]. SEVI enhanced
XMRV attachment and fusion while lowering the threshold
for infectivity by up to 4,000-fold. XMRV infectivity was
enhanced by SEVI in a wide range of diﬀerent cell types,
including primary prostatic epithelial and stromal cells [70].
XMRV infectivity in cell culture was similarly enhanced
by human semen, and this was most pronounced at low
viral doses. These results, and the presence of XMRV RNA
in prostate secretions, suggest sexual transmission as a
potential biological mechanism for viral spread, although
conﬁrmation by seroprevalence and other epidemiologic
studies is required before such a conclusion can be made.
However, XMRV infection of rhesus macaques by the IV
route showed that the virus traﬃcs to and infects prostate
epithelium within 6 to 7 days of infection [63]. In addition,
a separate study, reported in this issue by Sharma et al.,
demonstrates that XMRV infects the reproductive tracts
of both male and female macaques further suggesting the
possibility of sexual transmission [82].
5. Host Restriction of XMRV inProstate
CancerCellLines
Many host restriction factors are IFN regulated and col-
lectively contribute to the IFN-induced antiviral state [83].
For example, IFNs induce OAS proteins that produce the
2 –5 -oligo(rA) activators of RNase L. As a result, RNase
L suppresses replication of a wide range of viruses in cells
exposed to IFN [24]. Sustained activation of RNase L also
drives cells into apoptosis, a potential antitumor cell as well
as an antiviral mechanism [84, 85]. Therefore, RNASEL
mutations could contribute to prostate cancer by allowing
clonal expansion of mutant cells that have escaped apoptosis
and/or by allowing persistent infection by oncogenic viruses.
Accordingly, reduction in RNase L levels by RNAi decreased
the IFN antiviral eﬀe c ta g a i n s tX M R Vi nD U 1 4 5c e l l s[ 30].Advances in Virology 7
However, in another study decreasing levels of RNase L using
an RNAi approach did not enhance XMRV replication in
293T cells [32].
The human APOBEC3 family of cytidine deaminases
includes seven members (A3A to H) encoded on chro-
mosome 22 as a gene cluster [86]. A3G causes cytidine
deamination in viral minus strand DNA causing G→A
hypermutation in the coding strand thus potently inhibiting
infectivity and spread of HIV-1 lacking Vif protein [87,
88]. XMRV lacks an inhibitor such as Vif and is highly
susceptible to inhibition by A3G [44–47]. Accordingly, there
was characteristic G-to-A hypermutation of XMRV DNA in
T cell lines H9 and CEM that express A3G and A3F, but low
levels of such mutations in prostate cancer cell lines, LNCaP,
DU145, and 22Rv1, that lack A3G [45]. Primary prostatic
stromal ﬁbroblasts varied in expression of A3G mRNA
from undetectable to moderate levels [46]. These ﬁndings
suggest that prostate cancer cells and stromal ﬁbroblast
might provide a favorable environment for XMRV infection
and replication in vivo.
Groom et al. investigated the eﬀects of the murine
protein Fv1 and the TRIM5α family of proteins [44]. XMRV
was restricted by Fv1n and Fv1b but not restricted by
any of 13 TRIM5 proteins tested. However, XMRV was
highlysusceptibletoinhibitionbytheIFN-inducibleprotein,
tetherin, that links viruses to the plasma membrane during
budding [89].
6. Androgen Regulation of XMRV
Transcriptional control of the XMRV genome is mediated
by cis-acting elements in the 5 -LTR U3 region. This 390-
nucleotide segment contains the promoter and enhancers,
as well as two glucocorticoid response elements (GRE).
Other examples of GREs respond to glucocorticoids, min-
eralocorticoids, progesterone, and androgens. Furthermore,
tropism studies of cultured cells suggest a role for the
androgen receptor in promoting XMRV replication [30, 32,
34, 43]. XMRV was readily able to spread and replicate in
androgen receptor positive LNCaP cells, but not in various
other cell lines that lacked androgen receptor [32]. Dihy-
drotestosterone treatment of LNCaP cells caused a twofold
and threefold increase of XMRV transcription and replica-
tion, respectively [43]. Conversely, the androgen inhibitors,
casodex and ﬂutamide, inhibited XMRV replication by up
to threefold, which suggests that androgen ablation therapy
used in prostate cancer treatment could inhibit viral growth
[43]. A point mutation in one of the XMRV GREs led to
impaired androgen regulation of XMRV transcription and
replication [43]. Enhancer elements in the XMRV LTR could
impart androgen regulation to integrated host genes, thus
potentially contributing to oncogenesis.
7. Conclusions
There are a number of potential mechanisms by which a
retroviruscouldcauseprostatecancer.Retrovirusesgenerally
transform cells by insertional activation of an oncogene,
transduction of a host-derived oncogene, or oncogenesis
by a viral protein (e.g., the JSRV Env protein) [90, 91].
γretroviruses, which lack a host-derived oncogene, typically
cause cancer by insertion of the LTR near a cellular
proto-oncogene leading to its activation. One can, how-
ever, envision possible alternative oncogenic mechanisms.
For instance, viral infection in stromal cells might alter
the microenvironment thus indirectly promoting neoplas-
tic transformation. Infected stromal cells might induce
cytokines, chemokines, or growth factors, creating a micro-
environment conducive to tumorigenesis [92, 93]. Uncoor-
dinated integration of viral DNA ends is another potential
mechanism through which retroviruses may induce genomic
alterations. However, it was recently shown that XMRV
integration proceeds with high ﬁdelity and involves a
coordinated joining of the two viral DNA termini in the host
genome ﬂanked by a 4bp direct repeat of host DNA [68].
XMRV does not have direct transforming activity in
standard focus formation assays in ﬁbroblast and epithelial
cell lines [94, 95]. However, XMRV did rarely induce
transformation of a rat ﬁbroblast line, suggesting an indirect
mode ofaction.Mostlikely, inorderforXMRVtocontribute
to tumorigenesis through this mechanism, active viral repli-
cation with multiple integration events would be required
until integration occurred in a cellular oncogene [94].
Claims of novel human retroviruses have often been
met with considerable skepticism and resistance, earning the
moniker human “rumor viruses” and XMRV is certainly no
exception. While both PCR and non-PCR based evidence
from several diﬀerent laboratories collectively provide sup-
port for infections of some prostate cancer patients with
XMRV, or similar viruses, an extreme level of caution is
required to avoid laboratory contamination. Finally, only
hypothesis-driven research that directly tests for infection
and modes of pathogenesis for this virus can answer
questions about its importance in disease.
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